Brokerages forecast that Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) will post earnings per share (EPS) of ($0.06) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Diffusion Pharmaceuticals’ earnings. Diffusion Pharmaceuticals posted earnings of ($1.00) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 94%. The firm is expected to report its next earnings results on Monday, August 13th.
On average, analysts expect that Diffusion Pharmaceuticals will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.45) to ($0.43). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.26) per share, with EPS estimates ranging from ($0.26) to ($0.25). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Diffusion Pharmaceuticals.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last released its earnings results on Thursday, May 10th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.22).
DFFN has been the topic of a number of recent research reports. HC Wainwright set a $1.00 target price on shares of Diffusion Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, April 16th. ValuEngine raised shares of Diffusion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd.
Shares of NASDAQ:DFFN traded down $0.01 during midday trading on Friday, reaching $0.35. The company’s stock had a trading volume of 74,394 shares, compared to its average volume of 112,396. The company has a market capitalization of $18.21 million, a PE ratio of -0.31 and a beta of -1.37. Diffusion Pharmaceuticals has a 12-month low of $0.31 and a 12-month high of $2.97.
A hedge fund recently raised its stake in Diffusion Pharmaceuticals stock. Swift Run Capital Management LLC lifted its holdings in Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) by 261.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,508,017 shares of the company’s stock after buying an additional 1,814,806 shares during the quarter. Diffusion Pharmaceuticals makes up about 1.0% of Swift Run Capital Management LLC’s holdings, making the stock its 23rd biggest holding. Swift Run Capital Management LLC owned 4.96% of Diffusion Pharmaceuticals worth $1,369,000 at the end of the most recent quarter. Institutional investors own 7.66% of the company’s stock.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.
Featured Story: How are Outstanding Shares Different from Authorized Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.